Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 374
- Registration Number
- NCT00740883
- Locations
- 🇫🇷
Brest University Hospital, Brest, France
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
- Conditions
- Interventions
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 104
- Registration Number
- NCT00740493
- Locations
- 🇫🇷
Centre Hospitalier de Saint Brieuc, Saint Brieuc, France
🇫🇷Centre Hospitalier de Cornouaille, Quimper, France
🇫🇷CHU de Rennes, Rennes, France
Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 320
- Registration Number
- NCT00700895
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Patent Foramen Ovale in Cryptogenic Stroke Study
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 630
- Registration Number
- NCT00697151
- Locations
- 🇺🇸
Columbia College of Physicians and Surgeons, New York, New York, United States
Drug Interaction Study Between AZD3480 and Warfarin
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT00689637
- Locations
- 🇸🇪
Research SIte, Uppsala, Sweden
Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy
- Conditions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2011-03-21
- Lead Sponsor
- The Cooper Health System
- Target Recruit Count
- 10
- Registration Number
- NCT00683189
- Locations
- 🇺🇸
Cooper University Hospital, Camden, New Jersey, United States
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2589
- Registration Number
- NCT00680186
- Locations
- 🇨🇦
1160.46.02021 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇨🇦1160.46.02004 Boehringer Ingelheim Investigational Site, Saint John, New Brunswick, Canada
🇨🇦1160.46.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 3
- Registration Number
- NCT00673439
- Locations
- 🇺🇸
University of Louisville Hospital, Louisville, Kentucky, United States
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5614
- Registration Number
- NCT00643201
- Locations
- 🇺🇸
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
🇺🇸Great Falls Clinic, Llp, Great Falls, Montana, United States
🇺🇸Infectious Disease Of Indiana Psc, Carmel, Indiana, United States
Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 101
- Registration Number
- NCT00621491
- Locations
- 🇧🇷
Heart Institute (InCor) - Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.